ArticleMiddle East journal of digestive diseases2026
Frequency and Prognostic Value of KRAS, NRAS, and BRAF Mutations in Metastatic Colorectal Cancer: An Iranian Cohort Study.
Article in Middle East journal of digestive diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Colorectal cancer (CRC) is characterized by genetic mutations, particularly in the Rat sarcoma (RAS) and V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) oncogenes, which affect the prognosis and response to treatment. This study investigated the rates of Kristen Rat Sarcoma Viral oncogene homolog (K-RAS), neuroblastoma RAS viral oncogene homolog (N-RAS), and BRAF mutations and their association with 1-year survival among patients with metastatic CRC. Methods: This retrospective study included 83 patients with metastatic CRC from the oncology clinic at Shahid Beheshti Hospital, Qom, Iran. Demographic and clinical data, including mutation status, were collected. One-year patient survival was assessed. Results: In total, mutation frequencies were 47% for K-RAS, 14.5% for N-RAS, and 6% for BRAF. Conclusion: BRAF mutations were significantly associated with an age of diagnosis under 50 years; however, neither BRAF, KRAS, nor NRAS mutations demonstrated a significant association with other clinicopathological characteristics or 1-year survival in this cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.